Tilmacoxib
Tilmacoxib or JTE-522 is a COX-2 inhibitor and is an effective chemopreventive agent against rat experimental liver fibrosis.[1]
![]() | |
![]() | |
| Pharmacokinetic data | |
|---|---|
| Bioavailability | solution (64–88%) compared with capsule (22–40%). |
| Identifiers | |
IUPAC name
| |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| ChEBI | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C16H19FN2O3S |
| Molar mass | 338.397 g/mol g·mol−1 |
| 3D model (JSmol) | |
SMILES
| |
InChI
| |
See also
- NS-398
- Celecoxib
References
- Yamamoto, H., Kondo, M., Nakamori, S., Nagano, H., Wakasa, K., Sugita, Y., Chang-De, J., Kobayashi, S., Damdinsuren, B., Dono, K., Umeshita, K., Sekimoto, M., Sakon, M., Matsuura, N., Monden, M. (2003). "JTE-522, a cyclooxygenase-2 inhibitor, is an effective chemopreventive agent against rat experimental liver fibrosis1". Gastroenterology. 125 (2): 556–571. doi:10.1016/s0016-5085(03)00904-1. PMID 12891558.CS1 maint: multiple names: authors list (link)
This article is issued from
Wikipedia.
The text is licensed under Creative
Commons - Attribution - Sharealike.
Additional terms may apply for the media files.

